Hypertension - Pipeline Review, H2 2015

Date: December 31, 2015
Pages: 539
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: HF1F4E95D70EN
Leaflet:

Download PDF Leaflet

Hypertension - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Hypertension - Pipeline Review, H2 2015’, provides an overview of the Hypertension’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Hypertension
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Hypertension and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hypertension pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hypertension
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hypertension pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Hypertension Overview
Therapeutics Development
Hypertension - Therapeutics under Development by Companies
Hypertension - Therapeutics under Investigation by Universities/Institutes
Hypertension - Pipeline Products Glance
Hypertension - Products under Development by Companies
Hypertension - Products under Investigation by Universities/Institutes
Hypertension - Companies Involved in Therapeutics Development
Hypertension - Therapeutics Assessment
Drug Profiles
Hypertension - Recent Pipeline Updates
Hypertension - Dormant Projects
Hypertension - Discontinued Products
Hypertension - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Hypertension, H2 2015
Number of Products under Development for Hypertension - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Development by Companies, H2 2015 (Contd..4)
Number of Products under Development by Companies, H2 2015 (Contd..5)
Number of Products under Development by Companies, H2 2015 (Contd..6)
Number of Products under Development by Companies, H2 2015 (Contd..7)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Development by Companies, H2 2015 (Contd..6)
Products under Development by Companies, H2 2015 (Contd..7)
Products under Development by Companies, H2 2015 (Contd..8)
Products under Development by Companies, H2 2015 (Contd..9)
Products under Development by Companies, H2 2015 (Contd..10)
Products under Development by Companies, H2 2015 (Contd..11)
Products under Development by Companies, H2 2015 (Contd..12)
Products under Investigation by Universities/Institutes, H2 2015
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Hypertension - Pipeline by A1M Pharma AB, H2 2015
Hypertension - Pipeline by AbbVie Inc., H2 2015
Hypertension - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2015
Hypertension - Pipeline by Actelion Ltd, H2 2015
Hypertension - Pipeline by Afferent Pharmaceuticals, Inc., H2 2015
Hypertension - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2015
Hypertension - Pipeline by Anacor Pharmaceuticals, Inc., H2 2015
Hypertension - Pipeline by Arena Pharmaceuticals, Inc., H2 2015
Hypertension - Pipeline by Asahi Kasei Pharma Corp., H2 2015
Hypertension - Pipeline by Ascendis Pharma A/S, H2 2015
Hypertension - Pipeline by Bayer AG, H2 2015
Hypertension - Pipeline by Bial - Portela & Ca, S.A., H2 2015
Hypertension - Pipeline by Bio-inRen, H2 2015
Hypertension - Pipeline by Biolab Sanus Farmaceutica Ltda., H2 2015
Hypertension - Pipeline by BioLineRx, Ltd., H2 2015
Hypertension - Pipeline by Cardioxyl Pharmaceuticals, Inc., H2 2015
Hypertension - Pipeline by Carolus Therapeutics, Inc., H2 2015
Hypertension - Pipeline by Cellceutix Corporation, H2 2015
Hypertension - Pipeline by Celsion Corporation, H2 2015
Hypertension - Pipeline by China Grand Wuhan General Pharmaceutical Research Institute, H2 2015
Hypertension - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015
Hypertension - Pipeline by CJ HealthCare Corp., H2 2015
Hypertension - Pipeline by Complexa, Inc., H2 2015
Hypertension - Pipeline by Conatus Pharmaceuticals Inc., H2 2015
Hypertension - Pipeline by Corridor Pharmaceuticals Inc., H2 2015
Hypertension - Pipeline by Cytokinetics, Inc., H2 2015
Hypertension - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2015
Hypertension - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
Hypertension - Pipeline by DiaMedica Inc., H2 2015
Hypertension - Pipeline by Dong-A Socio Group, H2 2015
Hypertension - Pipeline by Eli Lilly and Company, H2 2015
Hypertension - Pipeline by Esperion Therapeutics, Inc., H2 2015
Hypertension - Pipeline by Galectin Therapeutics, Inc., H2 2015
Hypertension - Pipeline by Gilead Sciences, Inc., H2 2015
Hypertension - Pipeline by GlaxoSmithKline Plc, H2 2015
Hypertension - Pipeline by Glenveigh Medical, LLC, H2 2015
Hypertension - Pipeline by HanAll Biopharma Co., Ltd., H2 2015
Hypertension - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2015
Hypertension - Pipeline by Innopharmax Inc., H2 2015
Hypertension - Pipeline by Insmed Incorporated, H2 2015
Hypertension - Pipeline by IntelGenx Corp., H2 2015
Hypertension - Pipeline by Intercept Pharmaceuticals, Inc., H2 2015
Hypertension - Pipeline by Ionis Pharmaceuticals, Inc., H2 2015
Hypertension - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2015
Hypertension - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H2 2015
Hypertension - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2015
Hypertension - Pipeline by JW Pharmaceutical Corporation, H2 2015
Hypertension - Pipeline by Kowa Company, Ltd., H2 2015
Hypertension - Pipeline by Lacer, S.A., H2 2015
Hypertension - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2015
Hypertension - Pipeline by Les Laboratoires Servier SAS, H2 2015
Hypertension - Pipeline by LG Life Science LTD., H2 2015
Hypertension - Pipeline by LinXis B.V., H2 2015
Hypertension - Pipeline by Lotus Pharmaceutical Co., Ltd., H2 2015
Hypertension - Pipeline by LTT Bio-Pharma Co., Ltd., H2 2015
Hypertension - Pipeline by Merck & Co., Inc., H2 2015
Hypertension - Pipeline by Mezzion Pharma Co. Ltd., H2 2015
Hypertension - Pipeline by miRagen Therapeutics, Inc., H2 2015
Hypertension - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015
Hypertension - Pipeline by Neurim Pharmaceuticals Ltd, H2 2015
Hypertension - Pipeline by Nippon Kayaku Co., Ltd., H2 2015
Hypertension - Pipeline by Nippon Shinyaku Co., Ltd., H2 2015
Hypertension - Pipeline by Novartis AG, H2 2015
Hypertension - Pipeline by Noxamet Ltd, H2 2015
Hypertension - Pipeline by Omeros Corporation, H2 2015
Hypertension - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015
Hypertension - Pipeline by Peloton Therapeutics, Inc., H2 2015
Hypertension - Pipeline by Pfizer Inc., H2 2015
Hypertension - Pipeline by PharmaIN Corporation, H2 2015
Hypertension - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2015
Hypertension - Pipeline by Pluristem Therapeutics Inc., H2 2015
Hypertension - Pipeline by Proteo, Inc. (Inactive), H2 2015
Hypertension - Pipeline by Pulmokine, Inc., H2 2015
Hypertension - Pipeline by Quantum Genomics SA, H2 2015
Hypertension - Pipeline by Reata Pharmaceuticals, Inc., H2 2015
Hypertension - Pipeline by RedHill Biopharma Ltd., H2 2015
Hypertension - Pipeline by Respira Therapeutics, Inc., H2 2015
Hypertension - Pipeline by rEVO Biologics, Inc., H2 2015
Hypertension - Pipeline by Sanofi, H2 2015
Hypertension - Pipeline by Selten Pharma, Inc, H2 2015
Hypertension - Pipeline by Serodus ASA, H2 2015
Hypertension - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H2 2015
Hypertension - Pipeline by Silence Therapeutics Plc, H2 2015
Hypertension - Pipeline by Simcere Pharmaceutical Group, H2 2015
Hypertension - Pipeline by Sinoxa Pharma GmbH, H2 2015
Hypertension - Pipeline by SteadyMed Therapeutics, Inc., H2 2015
Hypertension - Pipeline by Suda Ltd, H2 2015
Hypertension - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015
Hypertension - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015
Hypertension - Pipeline by Symplmed, Inc., H2 2015
Hypertension - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015
Hypertension - Pipeline by The Medicines Company, H2 2015
Hypertension - Pipeline by Theravance Biopharma, Inc., H2 2015
Hypertension - Pipeline by Toray Industries, Inc., H2 2015
Hypertension - Pipeline by Torrent Pharmaceuticals Limited, H2 2015
Hypertension - Pipeline by TSH Biopharm Corporation Limited, H2 2015
Hypertension - Pipeline by vasopharm GmbH, H2 2015
Hypertension - Pipeline by VBS Pharmaceuticals, H2 2015
Hypertension - Pipeline by Vectura Group Plc, H2 2015
Hypertension - Pipeline by VG Life Sciences, Inc., H2 2015
Hypertension - Pipeline by Vicore Pharma AB, H2 2015
Hypertension - Pipeline by Yuhan Corporation, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Hypertension Therapeutics - Recent Pipeline Updates, H2 2015
Hypertension - Dormant Projects, H2 2015
Hypertension - Dormant Projects (Contd..1), H2 2015
Hypertension - Dormant Projects (Contd..2), H2 2015
Hypertension - Dormant Projects (Contd..3), H2 2015
Hypertension - Dormant Projects (Contd..4), H2 2015
Hypertension - Dormant Projects (Contd..5), H2 2015
Hypertension - Dormant Projects (Contd..6), H2 2015
Hypertension - Dormant Projects (Contd..7), H2 2015
Hypertension - Dormant Projects (Contd..8), H2 2015
Hypertension - Dormant Projects (Contd..9), H2 2015
Hypertension - Dormant Projects (Contd..10), H2 2015
Hypertension - Dormant Projects (Contd..11), H2 2015
Hypertension - Dormant Projects (Contd..12), H2 2015
Hypertension - Dormant Projects (Contd..13), H2 2015
Hypertension - Dormant Projects (Contd..14), H2 2015
Hypertension - Dormant Projects (Contd..15), H2 2015
Hypertension - Dormant Projects (Contd..16), H2 2015
Hypertension - Dormant Projects (Contd..17), H2 2015
Hypertension - Dormant Projects (Contd..18), H2 2015
Hypertension - Dormant Projects (Contd..19), H2 2015
Hypertension - Dormant Projects (Contd..20), H2 2015
Hypertension - Discontinued Products, H2 2015
Hypertension - Discontinued Products (Contd..1), H2 2015
Hypertension - Discontinued Products (Contd..2), H2 2015

LIST OF FIGURES

Number of Products under Development for Hypertension, H2 2015
Number of Products under Development for Hypertension - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

A1M Pharma AB
AbbVie Inc.
Ache Laboratorios Farmaceuticos S/A
Actelion Ltd
Afferent Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Anacor Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc.
Asahi Kasei Pharma Corp.
Ascendis Pharma A/S
Bayer AG
Bial - Portela & Ca, S.A.
Bio-inRen
Biolab Sanus Farmaceutica Ltda.
BioLineRx, Ltd.
Cardioxyl Pharmaceuticals, Inc.
Carolus Therapeutics, Inc.
Cellceutix Corporation
Celsion Corporation
China Grand Wuhan General Pharmaceutical Research Institute
Chong Kun Dang Pharmaceutical Corp.
CJ HealthCare Corp.
Complexa, Inc.
Conatus Pharmaceuticals Inc.
Corridor Pharmaceuticals Inc.
Cytokinetics, Inc.
Daewoong Pharmaceutical Co., Ltd.
Daiichi Sankyo Company, Limited
DiaMedica Inc.
Dong-A Socio Group
Eli Lilly and Company
Esperion Therapeutics, Inc.
Galectin Therapeutics, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Glenveigh Medical, LLC
HanAll Biopharma Co., Ltd.
Hanmi Pharmaceuticals, Co. Ltd.
Innopharmax Inc.
Insmed Incorporated
IntelGenx Corp.
Intercept Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Jeil Pharmaceutical Co., Ltd.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Jiangsu Hengrui Medicine Co., Ltd.
JW Pharmaceutical Corporation
Kowa Company, Ltd.
Lacer, S.A.
Lee's Pharmaceutical Holdings Limited
Les Laboratoires Servier SAS
LG Life Science LTD.
LinXis B.V.
Lotus Pharmaceutical Co., Ltd.
LTT Bio-Pharma Co., Ltd.
Merck & Co., Inc.
Mezzion Pharma Co. Ltd.
miRagen Therapeutics, Inc.
Mitsubishi Tanabe Pharma Corporation
Neurim Pharmaceuticals Ltd
Nippon Kayaku Co., Ltd.
Nippon Shinyaku Co., Ltd.
Novartis AG
Noxamet Ltd
Omeros Corporation
Ono Pharmaceutical Co., Ltd.
Peloton Therapeutics, Inc.
Pfizer Inc.
PharmaIN Corporation
PhaseBio Pharmaceuticals, Inc.
Pluristem Therapeutics Inc.
Proteo, Inc. (Inactive)
Pulmokine, Inc.
Quantum Genomics SA
Reata Pharmaceuticals, Inc.
RedHill Biopharma Ltd.
Respira Therapeutics, Inc.
rEVO Biologics, Inc.
Sanofi
Selten Pharma, Inc
Serodus ASA
Sihuan Pharmaceutical Holdings Group Ltd.
Silence Therapeutics Plc
Simcere Pharmaceutical Group
Sinoxa Pharma GmbH
SteadyMed Therapeutics, Inc.
Suda Ltd
Sumitomo Dainippon Pharma Co., Ltd.
Sun Pharma Advanced Research Company Ltd.
Symplmed, Inc.
Takeda Pharmaceutical Company Limited
The Medicines Company
Theravance Biopharma, Inc.
Toray Industries, Inc.
Torrent Pharmaceuticals Limited
TSH Biopharm Corporation Limited
vasopharm GmbH
VBS Pharmaceuticals
Vectura Group Plc
VG Life Sciences, Inc.
Vicore Pharma AB
Yuhan Corporation
Skip to top


Ocular Hypertension - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 127 pages
Portal Hypertension - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 73 pages
Omeros Corporation - Product Pipeline Review - 2016 US$ 1,500.00 Aug, 2016 · 115 pages
Longevity Biotech, Inc - Product Pipeline Review - 2015 US$ 1,200.00 Feb, 2015 · 29 pages

Ask Your Question

Hypertension - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: